Stockreport

Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF CAMBRIDGE, Mass., June 6, 2019 /PRNewswire/ -- Boston Biomedical, Inc. today announced the continuation of the CanStem303C study evaluating the safety and efficacy of in [Read more]